Literature DB >> 34242635

Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).

Christopher Ma1, Alain M Schoepfer2, Evan S Dellon3, Albert J Bredenoord4, Mirna Chehade5, Margaret H Collins6, Brian G Feagan7, Glenn T Furuta8, Sandeep K Gupta9, Ikuo Hirano10, Vipul Jairath7, David A Katzka11, Rish K Pai12, Marc E Rothenberg13, Alex Straumann14, Seema S Aceves15, Jeffrey A Alexander11, Nicoleta C Arva16, Dan Atkins17, Luc Biedermann14, Carine Blanchard18, Antonella Cianferoni19, Constanza Ciriza de Los Rios20, Frederic Clayton21, Carla M Davis22, Nicola de Bortoli23, Jorge A Dias24, Gary W Falk25, Robert M Genta26, Gisoo Ghaffari27, Nirmala Gonsalves10, Thomas Greuter28, Russell Hopp29, Karen S Hsu Blatman30, Elizabeth T Jensen31, Doug Johnston32, Amir F Kagalwalla33, Helen M Larsson34, John Leung35, Hubert Louis36, Joanne C Masterson37, Calies Menard-Katcher8, Paul A Menard-Katcher38, Fouad J Moawad39, Amanda B Muir40, Vincent A Mukkada41, Roberto Penagini42, Robert D Pesek43, Kathryn Peterson44, Philip E Putnam41, Alberto Ravelli45, Edoardo V Savarino46, Christoph Schlag47, Philipp Schreiner14, Dagmar Simon48, Thomas C Smyrk49, Jonathan M Spergel19, Tiffany H Taft10, Ingrid Terreehorst50, Tim Vanuytsel51, Carina Venter17, Mario C Vieira52, Michael Vieth53, Berber Vlieg-Boerstra54, Ulrike von Arnim55, Marjorie M Walker56, Joshua B Wechsler57, Philip Woodland58, John T Woosley59, Guang-Yu Yang60, Noam Zevit61, Ekaterina Safroneeva62.   

Abstract

BACKGROUND: End points used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments.
OBJECTIVE: We sought to develop a core outcome set (COS) for controlled and observational studies of pharmacologic and diet interventions in adult and pediatric patients with EoE.
METHODS: Candidate outcomes were generated from systematic literature reviews and patient engagement interviews and surveys. Consensus was established using an iterative Delphi process, with items voted on using a 9-point Likert scale and with feedback from other participants to allow score refinement. Consensus meetings were held to ratify the outcome domains of importance and the core outcome measures. Stakeholders were recruited internationally and included adult and pediatric gastroenterologists, allergists, dieticians, pathologists, psychologists, researchers, and methodologists.
RESULTS: The COS consists of 4 outcome domains for controlled and observational studies: histopathology, endoscopy, patient-reported symptoms, and EoE-specific quality of life. A total of 69 stakeholders (response rate 95.8%) prioritized 42 outcomes in a 2-round Delphi process, and the final ratification meeting generated consensus on 33 outcome measures. These included measurement of the peak eosinophil count, Eosinophilic Esophagitis Histology Scoring System, Eosinophilic Esophagitis Endoscopic Reference Score, and patient-reported measures of dysphagia and quality of life.
CONCLUSIONS: This interdisciplinary collaboration involving global stakeholders has produced a COS that can be applied to adult and pediatric studies of pharmacologic and diet therapies for EoE and will facilitate meaningful treatment comparisons and improve the quality of data synthesis.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eosinophilic esophagitis; clinical trials; end points; endoscopy; histology; histopathology; outcomes; patient-reported outcomes; quality of life; symptoms

Mesh:

Year:  2021        PMID: 34242635      PMCID: PMC8733049          DOI: 10.1016/j.jaci.2021.07.001

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  57 in total

Review 1.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

2.  Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.

Authors:  Alex Straumann; Alfredo J Lucendo; Stephan Miehlke; Michael Vieth; Christoph Schlag; Luc Biedermann; Cecilio Santander Vaquero; Constanza Ciriza de Los Rios; Christoph Schmoecker; Ahmed Madisch; Petr Hruz; Jamal Hayat; Ulrike von Arnim; Albert Jan Bredenoord; Stefan Schubert; Ralph Mueller; Roland Greinwald; Alain Schoepfer; Stephen Attwood
Journal:  Gastroenterology       Date:  2020-07-25       Impact factor: 22.682

3.  Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.

Authors:  Alain M Schoepfer; Ekaterina Safroneeva; Christian Bussmann; Tanja Kuchen; Susanne Portmann; Hans-Uwe Simon; Alex Straumann
Journal:  Gastroenterology       Date:  2013-08-13       Impact factor: 22.682

Review 4.  Eosinophilic esophagitis: diagnostic tests and criteria.

Authors:  Evan S Dellon
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

5.  Disease-Related Predictors of Health-Related Quality of Life in Youth With Eosinophilic Esophagitis.

Authors:  Mary K Lynch; Margaux J Barnes; Reed A Dimmitt; Lisa Martin; Marc E Rothenberg; Burel R Goodin
Journal:  J Pediatr Psychol       Date:  2018-05-01

6.  Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.

Authors:  Evan S Dellon; John T Woosley; Ashley Arrington; Sarah J McGee; Jacquelyn Covington; Susan E Moist; Jessica H Gebhart; Alexandra E Tylicki; Shiyan O Shoyoye; Christopher F Martin; Joseph A Galanko; John A Baron; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2019-03-11       Impact factor: 22.682

7.  Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment.

Authors:  Evan S Dellon; Cary C Cotton; Jessica H Gebhart; Leana L Higgins; RoseMary Beitia; John T Woosley; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-25       Impact factor: 11.382

8.  ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE).

Authors:  Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka
Journal:  Am J Gastroenterol       Date:  2013-04-09       Impact factor: 10.864

9.  Core Outcome Set-STAndards for Development: The COS-STAD recommendations.

Authors:  Jamie J Kirkham; Katherine Davis; Douglas G Altman; Jane M Blazeby; Mike Clarke; Sean Tunis; Paula R Williamson
Journal:  PLoS Med       Date:  2017-11-16       Impact factor: 11.069

10.  OMERACT: an international initiative to improve outcome measurement in rheumatology.

Authors:  Peter Tugwell; Maarten Boers; Peter Brooks; Lee Simon; Vibeke Strand; Leanne Idzerda
Journal:  Trials       Date:  2007-11-26       Impact factor: 2.279

View more
  3 in total

1.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2022-05-20       Impact factor: 14.290

2.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  Gastroenterology       Date:  2022-05-20       Impact factor: 33.883

3.  Development and technical validation of an artificial intelligence model for quantitative analysis of histopathologic features of eosinophilic esophagitis.

Authors:  Luisa Ricaurte Archila; Lindsey Smith; Hanna-Kaisa Sihvo; Thomas Westerling-Bui; Ville Koponen; Donnchadh M O'Sullivan; Maria Camila Cardenas Fernandez; Erin E Alexander; Yaohong Wang; Priyadharshini Sivasubramaniam; Ameya Patil; Puanani E Hopson; Imad Absah; Karthik Ravi; Taofic Mounajjed; Rish Pai; Catherine Hagen; Christopher Hartley; Rondell P Graham; Roger K Moreira
Journal:  J Pathol Inform       Date:  2022-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.